Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05690503 · ClinicalTrials.gov registry record · Phase 2
Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial
A Phase 2 study of Depressive Symptoms and Cognitive Dysfunction, sponsored by New York State Psychiatric Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05690503 is a Phase 2 study of Depressive Symptoms and Cognitive Dysfunction that is active but no longer recruiting, run by New York State Psychiatric Institute. The registered enrollment target is 12 participants, below the 262-participant average among 60 other Depressive Symptoms trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05690503, a Phase 2 study of Depressive Symptoms and Cognitive Dysfunction, is active but no longer recruiting, sponsored by New York State Psychiatric Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Post-acute sequelae of SARS-CoV2 (PASC), colloquially known as "long-COVID," is thought to affect between 10-30% of all COVID-19 survivors. Patients with PASC also report worsening behavioral health symptoms over time that include new-onset depression, anxiety, and even suicidal behavior. The purpose of this randomized, double-blind, controlled trial is to test the efficacy of a glutamate modulator among PASC patients suffering from new-onset or worsening of depressive symptoms.
Conditions Studied
Interventions
- DRUG CI-581a
- DRUG CI-581b
Study Locations (1)
New York
- New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-03-20 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05690503
The ClinicalTrials.gov registry entry for NCT05690503 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 262-participant average among 60 other Depressive Symptoms trials with a reported enrollment target (95% lower). The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Depressive Symptoms appearing as the primary indexed condition, and to 2 interventions - of which CI-581a is the first listed.
NCT05690503 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05690503 about?
NCT05690503 is a clinical study titled "Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial". Post-acute sequelae of SARS-CoV2 (PASC), colloquially known as "long-COVID," is thought to affect between 10-30% of all COVID-19 survivors. Patients with PASC also report worsening behavioral health symptoms over time that include new-onset depression, anxiety, and even suicidal behavior. The purpos...
What is the current status of trial NCT05690503?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2023-03-20. Estimated completion is 2025-12-31.
What conditions does trial NCT05690503 study?
This clinical trial studies the following conditions: Depressive Symptoms, Cognitive Dysfunction, Post Acute Sequelae of COVID-19.
What interventions are being tested in trial NCT05690503?
The interventions under investigation include: CI-581a (DRUG), CI-581b (DRUG).
Who is sponsoring clinical trial NCT05690503?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05690503 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Symptoms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cannabidiol for Reduction of Brain Neuroinflammation
RECRUITING · Phase 2
-
Beating the Blues for Your Heart
COMPLETED · Phase 2
-
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
COMPLETED · Phase 2
-
Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)
RECRUITING · Phase 4
-
Caregiver Stress and Sleep Study
RECRUITING · NA
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.